Here is the design of a clinical trial:

Official Title: A Randomized Comparative Effectiveness Trial Of Financial Incentives Versus Usual Care For Smokers Hospitalized In The Veterans Affairs Hospital System

Included conditions:
- Smoking
- Smoking, Tobacco
- Tobacco Use Disorder

Study Armgroups:
- {'label': 'Usual care', 'type': 'ACTIVE_COMPARATOR', 'description': 'Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital.', 'interventionNames': ['Behavioral: Smoking cessation counseling (Quitline)', 'Behavioral: Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)']}
- {'label': 'Financial Incentives', 'type': 'EXPERIMENTAL', 'description': "Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital. Financial incentives for: a) speaking with a coach from the Smoker's Quitline ($50), b) completion of another community-based smoking-cessation program ($50), and/or c) use of pharmacotherapies for smoking cessation at 2 weeks ($50); and d) for smoking cessation, confirmed with the use of a cotinine test at 2 months ($150); and e) for smoking cessation, confirmed with the use of a cotinine test at 6 months after study enrollment ($250).", 'interventionNames': ['Behavioral: Smoking cessation counseling (Quitline)', 'Behavioral: Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)', 'Behavioral: Financial incentives']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'Smoking cessation counseling (Quitline)', 'armGroupLabels': ['Financial Incentives', 'Usual care']}
- {'type': 'BEHAVIORAL', 'name': 'Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)', 'armGroupLabels': ['Financial Incentives', 'Usual care']}
- {'type': 'BEHAVIORAL', 'name': 'Financial incentives', 'armGroupLabels': ['Financial Incentives']}

Primary Outcomes:
- {'measure': 'Smoking abstinence assessed by self-reported and biochemically verified by salivary cotinine', 'description': 'Assessed by self-report questionnaire, and biochemically verified by salivary cotinine', 'timeFrame': '6 months'}

Please estimate the sample size based on the assumption: 
Significance level (α) = 0.05, power = 80%, participation rate = 60%, loss to follow-up rate = 10-15%.
Sample size
        We will enroll 182 smokers and expect a 60% participation rate. In addition, we expect a 10â15% loss to follow-up rate at 6Â months. We consider an absolute difference of approximately 20% in smoking cessation rates to be clinically substantial, where absolute differenceâ=â(rate1 â rate2). Therefore, this sample size (91 patients per arm) allows at least 80% power to detect a substantial clinical difference in smoking cessation rates between the control group (enhanced usual care alone arm) and intervention group (financial incentives plus enhanced usual care arm) with Î±â=â0.05.